```
=> d his

     (FILE 'REGISTRY' ENTERED AT 11:20:47 ON 22 MAY 2003)
                DEL HIS Y
                ACT EPPERSON679/A
               ---------
L1              STR
L2          517 SEA FILE=REGISTRY SSS FUL L1
               ---------
L3           80 S L2 AND 14/SZ
L4            4 S L2 AND 6-14/SZ
L5            1 S L2 AND 5-6-14/SZ
L6           85 S L3-L5

     FILE 'HCAPLUS' ENTERED AT 11:25:01 ON 22 MAY 2003
L7            2 S L6
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 11:25:46 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 MAY 2003  HIGHEST RN 518004-10-9
DICTIONARY FILE UPDATES:  20 MAY 2003  HIGHEST RN 518004-10-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d que stat l2
L1                STR
```














```
VAR G1=19/H/29/22
VAR G2=AK/CY/NH/24/26
VAR G3=NH/O
REP G4=(1-15) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  29
```

Claims 25-31

STEREO ATTRIBUTES: NONE
L2 517 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 59761 ITERATIONS 517 ANSWERS
SEARCH TIME: 00.00.06

=> d his l3-16

L3 80 S L2 AND 14/SZ
L4 4 S L2 AND 6-14/SZ
L5 1 S L2 AND 5-6-14/SZ
L6 85 S L2 AND L3-L5

} limited above search to claim 32 by ring size. → claim 32

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:26:30 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 May 2003 VOL 138 ISS 21
FILE LAST UPDATED: 21 May 2003 (20030521/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que nos l7
L1 STR
L2 517 SEA FILE=REGISTRY SSS FUL L1
L3 80 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND 14/SZ
L4 4 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND 6-14/SZ
L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND 5-6-14/SZ
L6 85 SEA FILE=REGISTRY ABB=ON PLU=ON (L3 OR L4 OR L5)
L7 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

=> d .ca hitstr l7 1-2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:425500 HCAPLUS
DOCUMENT NUMBER: 135:195778
TITLE: Activation of a terminal carboxylic acid by an internal oxazole: a novel synthesis of

macrocyclodepsipeptide

AUTHOR(S): Zhao, Gang; Sun, Xiaowen; Bienayme, Hugues; Zhu, Jieping
CORPORATE SOURCE: Institut de Chimie des Substances Naturelles, CNRS, Gif-sur-Yvette, 91198, Fr.

SOURCE: Journal of the American Chemical Society (2001), 123(27), 6700-6701
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:195778

AB A new concept for the construction of macrocyclodepsipeptides from simple and readily available starting materials has been developed. The sequence consists of (a) a three-component reaction of an aldehyde, an amino alc., and a dipeptide isocyanate and (b) a domino process involving an activation of the terminal carboxylic acid function by a built-in aminooxazole followed by a macrocyclization under acidic conditions. The synthesis is atom-economic since only a mol. of water and "MeO" is lost in the entire sequence. The overall process is also ecol. benign since LiOH and TFA are the only reagents used, while water and low-mol. wt. alc. (MeOH) are the only side products formed.

CC 34-3 (Amino Acids, Peptides, and Proteins)

IT 357277-90-8P 357277-91-9P 357277-92-0P 357277-93-1P 357277-94-2P
357277-95-3P 357277-96-4P 357277-97-5P 357277-98-6P 357277-99-7P
357278-00-3P 357278-01-4P 357278-02-5P 357278-03-6P
357278-04-7P 357278-05-8P 357278-06-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of macrocyclodepsipeptide involving process of activation of terminal carboxylate by built-in aminooxazole and macrocyclization)

IT **357278-00-3P 357278-01-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of macrocyclodepsipeptide involving process of activation of terminal carboxylate by built-in aminooxazole and macrocyclization)

RN 357278-00-3 HCAPLUS

CN Glycine, (2S)-2-[(4-hydroxybutyl)amino]octanoyl-L-phenylalanyl-N-methyl-, (3.fwdarw.1)-lactone (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 357278-01-4 HCAPLUS

CN Glycine, (2S)-2-[(4-hydroxybutyl)amino]octanoyl-D-phenylalanyl-N-methyl-, (3.fwdarw.1)-lactone (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:265440 HCAPLUS
DOCUMENT NUMBER: 134:281140
TITLE: Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
INVENTOR(S): Deslongchamps, Pierre; Dory, Yves; Berthiaume, Gilles; Ouellet, Luc; Lan, Ruoxi
PATENT ASSIGNEE(S): Neokimia, Inc., Can.
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025257	A2	20010412	WO 2000-CA1151	20001004
WO 2001025257	A3	20011206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218403	A2	20020703	EP 2000-965687	20001004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511387	T2	20030325	JP 2001-528200	20001004

PRIORITY APPLN. INFO.: CA 1999-2284459 A 19991004
WO 2000-CA1151 W 20001004
OTHER SOURCE(S): MARPAT 134:281140

AB A library of macrocyclic compds. of formula cyclo[N(X)(CH2)xCHR1CO-A-B-C-T] [A is a bivalent radical -COCHR2(CH2)yNH- or -(CH2)y-, or a covalent bond; B is -COCHR3(CH2)zNH-, -(CH2)z, or a covalent bond; C is -COCHR4(CH2)tNH-, -(CH2)t, or a covalent bond; R1-R4 = H, Me, i-Pr, i-Bu, s-Bu, benzyl, 3-indolyl, methylthioethyl, etc.; x, y, z, t = 0-2; X = arylsulfonyl, MeSO2, CF3SO2, H, CHO, MeCO, acyl, carbamoyl, 2-benzothiazolylsulfonyl, etc.; T is a radical -Y-L-Z-, where Y is CH2 or CO, Z is NH or O, and L is a bivalent radical] were prepd. in a

combinatorial manner for use in carrying out screening assays or as intermediates for the synthesis of other compds. of pharmaceutical interest. Thus, a tripeptide library (135 members) was prepd. by the soln. phase method. This library consists of a linear sequence of three natural L-.alpha.-amino acids linked together by an aliph. chain with 4 or 5 carbons in a head to tail manner. The first amino acids are glycine, leucine and methionine, the second ones are glycine, histidine(Doc), leucine, proline and valine, and the third amino acids are glycine, methionine and phenylalanine. An example is c-B-GGG-1 which is triglycine contg. an an N-2-thiazolylsulfonyl group (B for betsyl) and linked by (E)-CH2CH:CHCH2CH2NH, resulting from alkylation with 5-(tert-butoxycarbonyamino)-trans-2-penten-1-ol, deprotection, and cyclization.

IC ICM C07K001-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 63

IT 2824-46-6P, 2-Benzothiazolesulfonyl chloride 2935-90-2P, Methyl 3-mercaptopropionate 30250-57-8P 58885-58-8P 58885-60-2P 64244-47-9P 102845-66-9P 128490-08-4P 173254-34-7P 214749-90-3P 333438-36-1P **333438-38-3P 333438-40-7P** 333438-48-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial synthesis of libraries of macrocyclic compds. useful in drug discovery)

IT 333435-69-1P 333435-71-5P 333435-73-7P 333435-75-9P 333435-77-1P
333435-79-3P 333435-81-7P 333435-83-9P 333435-85-1P 333435-87-3P
333435-89-5P 333435-91-9P 333435-93-1P 333435-95-3P 333435-97-5P
333435-98-6P 333436-00-3P 333436-02-5P 333436-05-8P 333436-07-0P
333436-09-2P 333436-11-6P 333436-14-9P 333436-16-1P 333436-19-4P
333436-20-7P 333436-23-0P 333436-25-2P 333436-28-5P 333436-30-9P
333436-33-2P 333436-36-5P 333436-38-7P 333436-40-1P 333436-42-3P
333436-44-5P 333436-46-7P 333436-48-9P 333436-50-3P 333436-52-5P
333436-54-7P 333436-56-9P 333436-58-1P 333436-60-5P 333436-62-7P
333436-64-9P 333436-66-1P 333436-68-3P
333436-70-7P 333436-71-8P 333436-72-9P
333436-74-1P 333436-75-2P 333436-77-4P
333436-79-6P 333436-81-0P 333436-83-2P
333436-85-4P 333436-87-6P 333436-89-8P
333436-91-2P 333436-93-4P 333436-94-5P
333436-96-7P 333436-98-9P 333437-00-6P
333437-02-8P 333437-04-0P 333437-06-2P
333437-09-5P 333437-11-9P 333437-13-1P 333437-15-3P
333437-17-5P 333437-19-7P 333437-21-1P 333437-23-3P 333437-25-5P
333437-27-7P 333437-29-9P 333437-31-3P
333437-33-5P 333437-35-7P 333437-37-9P
333437-39-1P 333437-41-5P 333437-43-7P
333437-45-9P 333437-47-1P 333437-49-3P
333437-51-7P 333437-53-9P 333437-55-1P
333437-56-2P 333437-58-4P 333437-60-8P
333437-62-0P 333437-64-2P 333437-66-4P
333437-68-6P 333437-70-0P 333437-72-2P
333437-74-4P 333437-76-6P 333437-78-8P
333437-80-2P 333437-82-4P 333437-84-6P
333437-86-8P 333437-88-0P 333437-90-4P
333437-92-6P 333437-94-8P 333437-96-0P
333437-98-2P 333438-01-0P 333438-03-2P 333438-05-4P
333438-07-6P 333438-09-8P 333438-11-2P 333438-13-4P 333438-15-6P
333438-17-8P **333438-19-0P 333438-21-4P**
333438-23-6P 333438-24-7P 333438-26-9P
333438-28-1P 333438-30-5P 333438-32-7P
333438-34-9P 333438-42-9P **333438-44-1P**

333438-46-3P 333438-50-9P 333438-51-0P 333438-52-1P
333438-53-2P 333438-54-3P 333438-56-5P 333438-58-7P 333438-61-2P
333438-63-4P 333438-65-6P 333438-67-8P 333438-69-0P 333438-71-4P
333438-73-6P 333438-75-8P 333438-77-0P 333438-79-2P 333438-81-6P
333438-83-8P 333438-85-0P 333438-86-1P 333438-88-3P 333438-90-7P
333438-91-8P 333438-93-0P 333438-95-2P **333439-03-5P**
333439-06-8P 333439-09-1P 333439-10-4P
333439-13-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinatorial synthesis of libraries of macrocyclic compds. useful in drug discovery)

IT **333438-38-3P 333438-40-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial synthesis of libraries of macrocyclic compds. useful in drug discovery)

RN 333438-38-3 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333438-40-7 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **333436-64-9P 333436-66-1P 333436-68-3P**
333436-70-7P 333436-71-8P 333436-72-9P
333436-74-1P 333436-75-2P 333436-77-4P
333436-79-6P 333436-81-0P 333436-83-2P
333436-85-4P 333436-87-6P 333436-89-8P
333436-91-2P 333436-93-4P 333436-94-5P
333436-96-7P 333436-98-9P 333437-00-6P
333437-02-8P 333437-04-0P 333437-06-2P
333437-09-5P 333437-27-7P 333437-29-9P
333437-31-3P 333437-33-5P 333437-35-7P
333437-37-9P 333437-39-1P 333437-41-5P
333437-43-7P 333437-45-9P 333437-47-1P
333437-49-3P 333437-51-7P 333437-53-9P
333437-55-1P 333437-56-2P 333437-58-4P
333437-60-8P 333437-62-0P 333437-64-2P
333437-66-4P 333437-68-6P 333437-70-0P
333437-72-2P 333437-74-4P 333437-76-6P
333437-78-8P 333437-80-2P 333437-82-4P
333437-84-6P 333437-86-8P 333437-88-0P
333437-90-4P 333437-92-6P 333437-94-8P
333437-96-0P 333437-98-2P 333438-19-0P
333438-21-4P 333438-23-6P 333438-24-7P
333438-26-9P 333438-28-1P 333438-30-5P
333438-32-7P 333438-34-9P 333438-44-1P
333438-46-3P 333439-03-5P 333439-06-8P
333439-09-1P 333439-10-4P 333439-13-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinatorial synthesis of libraries of macrocyclic compds. useful in drug discovery)

RN 333436-64-9 HCAPLUS

CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 333436-66-1 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-68-3 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-70-7 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-71-8 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-72-9 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-74-1 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-75-2 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-77-4 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-79-6 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-81-0 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-83-2 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-85-4 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-87-6 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 333436-89-8 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-91-2 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-93-4 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-94-5 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-96-7 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333436-98-9 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-00-6 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-02-8 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





RN 333437-04-0 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-06-2 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-09-5 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-27-7 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-29-9 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-31-3 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-33-5 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





RN 333437-35-7 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-37-9 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-39-1 HCAPLUS
CN Glycine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-41-5 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-43-7 HCAPLUS
CN L-Methionine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-45-9 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333437-47-1 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)



RN 333437-49-3 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-51-7 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-53-9 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-55-1 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-56-2 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-58-4 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-60-8 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-62-0 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionylglycyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-64-2 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-66-4 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-68-6 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-70-0 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-72-2 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-74-4 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-76-6 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-78-8 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-80-2 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-1-[[2-methyl-1-(1-methylethyl)propoxy]carbonyl]-L-histidyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-82-4 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-84-6 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-86-8 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-88-0 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 333437-90-4 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-92-6 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-94-8 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-96-0 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333437-98-2 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-19-0 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-21-4 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-23-6 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)glycyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-24-7 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 333438-26-9 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-28-1 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-leucyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-30-5 HCAPLUS
CN Glycine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-32-7 HCAPLUS
CN L-Methionine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-34-9 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-(2-benzothiazolylsulfonyl)-L-methionyl-L-valyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333438-44-1 HCAPLUS
CN L-Phenylalanine, N-[(2Z)-4-amino-2-butenyl]-N-formyl-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 333438-46-3 HCAPLUS
CN L-Phenylalanine, N-(4-amino-2-butynyl)-N-formyl-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333439-03-5 HCAPLUS
CN L-Aspartic acid, N2-[(2Z)-4-amino-2-butenyl]-L-arginylglycyl-, (31.fwdarw.1)-lactam, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 333439-06-8 HCAPLUS
CN L-Aspartic acid, N2-[(2Z)-4-amino-2-butenyl]-L-arginylglycyl-, (31.fwdarw.1)-lactam, monobutanoate (9CI) (CA INDEX NAME)

CM 1

CRN 333439-05-7
CMF C16 H27 N7 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 107-92-6
CMF C4 H8 O2



RN 333439-09-1 HCAPLUS
CN L-Phenylalanine, N-[[2-(aminomethyl)phenyl]methyl]-L-methionyl-L-leucyl-, (3.fwdarw.1)-lactam, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 333439-08-0
CMF C28 H38 N4 O3 S



CM 2

CRN 65-85-0
CMF C7 H6 O2



RN 333439-10-4 HCAPLUS
CN L-Aspartic acid, N-[[2-(aminomethyl)phenyl]methyl]-L-.alpha.-glutamyl-L-prolyl-, (31.fwdarw.1)-lactam, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

RN 333439-13-7 HCAPLUS
CN L-Aspartic acid, N2-[[2-(aminomethyl)phenyl]methyl]-L-lysyl-L-histidyl-, (31.fwdarw.12)-lactam, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 333439-12-6
CMF C24 H33 N7 O5



CM 2

CRN 144-62-7
CMF C2 H2 O4